Headline: Dishman Carbogen Amcis Limited Sets Date for Q2 FY26 Earnings Conference Call

Dishman Carbogen Amcis Limited (Scrip Code: 540701) has announced a conference call scheduled for November 5, 2025, at 15:00 IST to discuss its financial results for the second quarter of FY26, concluding on September 30, 2025. This call is a crucial opportunity for investors and analysts to gain insights into the company's performance and outlook.

The call will feature key management personnel, including Mr. Harshil Dalal, Global CFO, and Mr. Stephan Fritschi, CEO of Carbogen Amcis Entities. The company has established itself as a leading Contract Development and Manufacturing Organization (CDMO) since its inception in 1983, offering a comprehensive range of services, including the development and supply of Active Pharmaceutical Ingredients (APIs) and high-potent APIs across global facilities in Switzerland, the UK, France, the Netherlands, India, and China.

Dishman Carbogen Amcis Limited's expertise extends to niche products such as Phase Transfer Catalysts and Vitamin D Analogues, catering to innovator pharmaceutical companies worldwide. The Q2 FY26 results will be released on November 4, providing a foundation for the upcoming discussions.

Investors interested in participating can pre-register for the call to avoid long waiting times. For international participants, toll-free numbers are available, including options for the USA and the UK. Additional contact details and resources are accessible on the company’s official website at www.imdcal.com.

Stay tuned for what promises to be an insightful conference call as Dishman Carbogen Amcis continues to enhance its position in the pharmaceutical manufacturing sector.